How to differentiate in an overcrowded generics market? It's been 40 years since the growth of the generic drug market was fueled in the U.S. The Hatch-Waxman Amendments allowed generic drug manufacturers to demonstrate bioequivalence through pharmacokinetic studies, avoiding clinical trials. 📈 In 1984 only 19% of all prescription drug purchases in the U.S. were generics. 📈 By 2004, this grew to more than 53%. 📈 Today, generic drugs account for more than 90% of prescriptions filled in the U.S. Generics are generics, which means no differentiation. When your product is the same, your service is key. ✅ Go further than simple product development. This means actively listening to and understanding your client's needs. We perform a good market analysis, study market share in our client's relevant markets, and analyze competitor pricing to provide solutions to our customers to improve their market share. We are an agile company backed by the manufacturing resources of the Polpharma Group. We are there for you. Check it out: https://lnkd.in/d9kquK8x #YesYouHealth #Farmaprojects #Polpharma #B2BPharma #R&D #Generics
